A5088970562- Neuroblastoma Research and Treatments
- Protein Degradation and Inhibitors
- Genetics and Neurodevelopmental Disorders
- MicroRNA in disease regulation
- Signaling Pathways in Disease
- Ubiquitin and proteasome pathways
- RNA modifications and cancer
- Cell death mechanisms and regulation
- Endoplasmic Reticulum Stress and Disease
- interferon and immune responses
- Genomics and Chromatin Dynamics
- Chromatin Remodeling and Cancer
Vall d'Hebron Institut de Recerca
2014-2020
Universitat Autònoma de Barcelona
2017-2019
Current therapies for most non-infectious diseases are directed at or affect functionality of the human translated genome, barely 2% all genetic information. By contrast, therapeutic potential targeting transcriptome, ~ 70% remains largely unexplored. RNA therapeutics is an emerging field that widens range druggable targets and includes elements such as microRNA. Here, we sought to screen microRNA with tumor-suppressive functions in neuroblastoma, aggressive pediatric tumor sympathetic...
// Aroa Soriano 1 , Laia París-Coderch Luz Jubierre Alba Martínez 2 Xiangyu Zhou 3 Olga Piskareva 4 Isabella Bray Isaac Vidal Ana Almazán-Moga Carla Molist Josep Roma José R. Bayascas Oriol Casanovas Raymond L. Stallings Sánchez de Toledo Soledad Gallego Miguel F. Segura Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Institute (VHIR)-UAB, Barcelona, Spain Tumor Angiogenesis Group, Catalan Oncology-IDIBELL, L'Hospitalet Llobregat, Institut Neurociències...
MicroRNAs are critical regulators of gene networks in normal and abnormal biological processes. Focusing on invasive ductal breast cancer (IDC), we have found dysregulated expression tumor samples several microRNAs, including the miR-200 family, along progression from primary tumors to distant metastases, further reflected higher blood levels miR-200b miR-7 IDC patients with regional or metastases relative node-negative tumors. Forced miR-200s MCF10CA1h mammary cells induced an enhanced...
Neuroblastoma is the leading cause of cancer death in children aged 1 to 4 years. Particularly, five-year overall survival for high-risk neuroblastoma below 50% with no curative options when refractory or relapsed. Most current therapies target cell division and proliferation, thereby inducing DNA damage programmed death. However, aggressive tumours often present alterations these processes are resistant therapy. Therefore, exploring alternative pathways induce tumour will provide new...
Abstract Neuroblastoma (NBL) is the most common solid tumor in infants and accounts for approximately 15% of cancer deaths children. Neuroblastomas are very heterogeneous, with prognosis ranging from spontaneous regression to aggressive clinical course, often become refractory all current forms treatment. While low intermediate-risk patients have good prognosis, high-risk poor need intense chemotherapy. Despite treatment, 60-70% will die, mainly due resistance therapy metastasis. Owing...